The promising in vivo behaviour exhibited by the new selective antagonist 7 further supports that 5-HT6R antagonists represent a step toward the identification of new cognitive enhancers for the treatment of AD and other psychiatric and neurological disorders with associated cognitive dysfunction. Here, HTR6 is linked to Alzheimer disease.